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ABSTRACT 
 
Background: Breast cancer is the leading cause of cancer death in women. 
Despite major advances in breast cancer research, the recurrence of cancer 
represents a serious obstacle to successful treatment; deregulation in cell 
cycle proteins have been implicated in different cancers including  breast. A 
pharmacological approach to inhibit cyclin - dependent kinases 4 and 6 
(CDK 4/6) using Palbociclib, a highly selective small molecule inhibitor,  was 
used to evaluate the effects of this inhibitor on cell proliferation of  4 different 
breast cancer cells subtypes (MCF-7, MDA-MB-231,BT474Z, MCF-7/her2 
transfected).  
 
Methods: ERα and Cyclin D1 expression has been evaluated on 34 breast 
cancer specimens; 4 human immortalized breast cancer cell lines (BT474Z, 
MCF-7, MCF7/her2 transfected, MDA-MB-231) and one cell line derived 
from breast cancer tissue patient (K90) have been treated with increasing 
concentrations of Palbociclib (cyclin D1-CDK4/6 inhibitor) alone and in 
combination with AI Formestane; cell proliferation was evaluated by MTT 
assay and cell count. Cell cycle analysis and protein expression have been 
performed by Facs and WB. 
 
Results: ERα-positive MCF-7 cells are more sensitive to Palbociclib 
compared to the other breast cancer cell subtypes; Palbociclib displays a 
cytostatic effect by inhibiting cell viability and proliferation; the inhibitory 
effect of Palbociclib is based on breast cancer cells subtypes through 
modulation of expression of G0/G1 regulators (cyclin D1, p27, Rb and 
phospo-Rb). The combination of Palbociclib with Formestane showed a 
greater inhibition of cell proliferation compared with Palbociclib alone. 
 
Conclusion: This study suggests a potential role of CDK 4/6 inhibitor 
Palbociclib on different breast cancer subtypes and identifies Luminal A and 
Luminal B breast cancer as possible target of Palbociclib in clinical setting. 
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1.BACKGROUND 
 
 
1.1Epidemiological data of Breast Cancer 
 
Breast cancer is the second most common cancer in the world and, 
certainly, the most frequent cancer among women with an estimated 1.67 
million new cancer cases diagnosed in 2012 equivalent to 25% of all 
cancers. This neoplasia is the most common cancer in women both in more 
and less developed regions with slightly more cases in less developed 
(883.000 cases) than in more developed (794.000 cases) regions.  
Incidence rates vary nearly four-fold across the world regions, with lower 
rates  (27 per 100.000 in Middle Africa) compared to higher rates (92 per 
100.000 in Northern America) depending on the specific geographical 
regions. 
 
Breast cancer represents the fifth cause of death from cancer overall, it is 
the second cause of cancer death in more developed regions after lung 
cancer; however, it is the most frequent cause of cancer death in women in 
less developed regions. The range in mortality rates between world regions 
is less than that for incidence because of a better survival of breast cancer 
in developed regions, with rates ranging from 6 per 100.000 in Eastern Asia 
to 20 per 100.000 in Western Africa.  
 
 Figure 1 shows incidence and mortality of breast cancer according to the 
related countries [1]. 
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Figure 1. 
Incidence and mortality of breast cancer in the world, the incidence is higher in more 
developed countries as Northern America and West Europe compared to  less developed 
countries,  mortality rate compared to incidence is higher in countries less developed such 
as West Africa and Melanesia [1]. 
 
 
 
1.2 Risk factors 
The risk of developing breast cancer is due to genetic, endocrine, dietary, 
environmental factors, and to lifestyle habits. They can be divided into two 
groups: intrinsic (related to individual biological features) and extrinsic 
(closely related to lifestyle or medical intervention) factors. Sex, age, race, 
natural hormonal changes during life, and specific genetic alterations 
represent the most important intrinsic risk factors. Sex is crucial because the 
neoplasm is diagnosed predominantly in women and sporadically (less than 
1 %) in men [2]. 
In addition, race also represents a very important intrinsic factor since 
differences in breast cancer incidence and aggressiveness have been 
reported. In fact, caucasian women are more susceptible to develop breast 
cancer compared to african-american and hispanic women, which, in turns, 
although having a lower incidence of breast cancer, are diagnosed at a 
younger age with an aggressive, often triple negative,  breast cancer [3]. 
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A direct correlation exists between the levels and duration of mammary 
gland exposure to estrogens and the onset of the disease. Estrogens 
modulate the various stages of female reproductive system development, 
the secondary sexual characteristics and stimulate the mammary gland 
during their entire fertile period. The risk of cancer is related to early 
menarche, age at first pregnancy, number of pregnancies to term, the length 
of breastfeeding and late menopause since in such physiological conditions 
changes in estrogen levels can cause a greater or lesser susceptibility to the 
development of breast cancer [4]. 
Although the majority of breast cancers are sporadic, 5% -7% are correlated 
to hereditary factors, a quarter of them determined by mutations of BRCA-1 
and BRCA-2 genes. In women with mutations in the BRCA-1 gene the risk 
of developing breast cancer is equal to 65%; in women with mutations in the 
BRCA-2 gene it is  of 40% [5] . 
 
  Other hereditary factors are: 
- Mutations in ATM (Ataxia Telangiectasia Mutated) or CHEK2 genes [6] 
- Mutations in PALB2 gene [7] 
  - Li-Fraumeni Syndrome (p53 mutation) 
- Cowden syndrome (mutation of the PTEN gene) 
- Ataxia-telangiectasia,Peutz-Jeghers syndrome 
The most important extrinsic risk factors are related to lifestyle, such as 
dietary habits, and the use of oral contraception. Indeed, eating products 
that are rich in fat together with a low consumption of fruit and vegetables  
may be a factor promoting neoplastic trasformation in mammary gland [8]; 
on the contrary, a low fat diet contributes to decrease the possibility to 
develop cancer and reduces the risk of recurrence after the primary surgical 
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procedure [9]. Also, bad habits, such as excessive alcohol consumption, 
may increase the chance of developing breast cancer [10]. Finally, the use 
of oral contraceptives or hormone replacement therapy can alter the normal 
hormonal balance leading to breast tumor progression [11]. 
     
1.3 Breast cancer molecular subtypes 
 
Breast cancer is a highly heterogeneous disease characterized by multiple 
tumoral subtypes with several biological features. The increased 
understanding of the process of tumorigenesis and the introduction of new 
technologies have allowed the identification of different subtypes of breast 
cancer by enabling more precise management of the neoplasm, but also 
increasing the level of complexity in the total understanding of the 
pathology. Biomarkers inclusive of estrogen receptor (ER), progesterone 
receptor (PR),androgen receptor (AR) and human epidermal growth factor 
receptor 2 (HER2) are used for basic breast cancer subtyping.ER plays 
crucial role in breast carcinogenesis and its inhibition was the first step of 
endocrine therapy; ER-positive tumors are differentiated and less 
aggressive than ER-negative tumors. 
ER-negative tumors do not respond to endocrine therapy whereas about 
50% of ER-positive patients are responsive to inhibitor of estrogens [12] 
[13].  
PR-positive tumors, in few cases (0.1% to 10%) are ER–negative [14] but 
most of PR-positive breast tumors (55% to 65%) are also positive for ER 
expression [15] [16].  
HER-2 amplification or overexpression occurs in about 20% - 30 %of 
invasive ductal breast cancer; the definition of HER 2 state represents a 
routine investigation in clinical practice for the use of targeted agents[17] . 
In addition, the definition of specific biomarkers of proliferation 
(Ki67,TOP2A) allowed a more accurate evaluation of the clinical implication. 
Triple negative (ER-negative, PR–negative, HER2–negative) breast tumors 
represent the most aggressive and problematic tumors to cure, due to the 
absence of target receptors. Breast cancer patients with these 
characteristics are divided into basal and non-basal depending on the 
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presence of specific markers such as cytokeratins 5,14,17,18, EGFR, 
vimentin, P-Cadherin. Furthermore, the definition of EMT biomarkers (Zeb, 
Twist, Snail, Claudins) and biomarkers of stemness (CD44, CD24, EpCam, 
Aldh1, Muc1, Thy1) has increased the level of complexity in understanding 
breast cancer tumorigenesis [18]. 
In table 1 are summarized the main breast cancer subtypes. 
 
 
Table 1. 
Summary of molecular breast cancer subtypes with detailed expression patterns and 
clinical implications. [18].  
 
 
 
 10 
1.4 Current breast cancer therapy  
 
1.4.1 Endocrine Therapy 
Endocrine therapy represents the first treatment option for estrogens 
receptor positive and HER2 negative breast cancer patients. Endocrine 
therapy, which applies to menopausal women, gives fewer side effects and 
better quality of life compared to chemotherapy.  
In patients with breast cancer and premenopausal status the combination of 
LhRh analogue, which are able to block the production of ovarian estrogens 
by inhibiting hypothalamic pituitary, and tamoxifen represents the first line of 
treatment. 
Tamoxifen, classified as a selective estrogens receptor modulator (SERM),  
contrasts proliferative stimulus and acts as an antagonist of ERα. Tamoxifen 
mainly inhibits the proliferation of ER-positive breast cancer cells by 
competing with estrogens binding to ERα [19]. In menopausal and post-
menopausal women, aromatase inhibitors (AIs), which interrupt the 
production of estrogens in these women, are used as therapeutic agents for 
metastatic breast cancer. Moreover, these inhibitors block the enzyme 
aromatase, which turns the hormone androgen into estrogens in the body. 
The decrease of this synthesis determines a minor contribution of estrogens 
available to stimulate the growth of ER-positive breast cancer cells. 
AIs are classified according to the date of discovery: 
- AIs of first generation or inactivating steroidal enzyme are 
analogues of androstenedione that irreversibly bind to the same site 
of the aromatase molecule; Aminoglutemide was the first drug used 
in clinical practice. 
 
- AIs of second generation (non-steroidal structure) reversibly bind to 
the heme group of the aromatase enzyme; formestane is the main 
drug in this group. 
 
- AIs of third generation are anastrozole, letrozole, examestane; 
unlike others AIs, these compound are orally administered. 
Anastrozole and letrozole are non-steroidal inhibitors whereas 
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exemestane is a steroidal inactivator. These third-generation AIs 
have demonstrated greater efficacy than previous inhibitors, and 
fewer side effects. 
 
Fulvestrant is a recent drug used for endocrine breast cancer treatment. It is 
an ER antagonist that disrupts ER dimerization and nuclear localization, by 
blocking ER-mediated transcriptional activity and accelerating receptor 
degradation. It has been proven to be effective on breast cancer 
progression disease after treatment with tamoxifen and aromatase inhibitors 
[20] [21]. 
 
1.4.2 Breast cancer therapy against HER2 
Breast cancer therapy against HER2 are based on specific targeted agent: 
 
-Trastuzumab is a human monoclonal antibody that binds tothe surface of 
HER2-positive cancer cells.Breast cancer in vivo  models and clinical trials 
have demonstrated that trastuzumab has not only citostatic but also 
cytotoxic properties, due to the activation of immune system through the 
activation of natural killer cells, which leads to the lysis of cancer cells bound 
to trastuzumab [22]. 
 
-Pertuzumab is a humanized recombinant monoclonal antibody; it  blocks 
the growth factor HER2 in combination with trastuzumab. This drug was 
developed to prevent the HER2 receptor binding to other HER receptors 
(EGFR / HER1, HER 3 and HER 4) [23]. 
 
-Lapatinib is a kinase inhibitor of the intracellular tyrosine kinase domains of 
both EGFR and HER2 receptors. In particular, lapatinib targets the 
intracellular tyrosine kinase domains of these two receptors and induces 
apoptosis and inhibition of tumor cell growth. Compared to Herceptin, which 
targets the HER2 protein on the outside of the cell membrane, lapatinib is a 
small molecule that enters the cell and blocks the transduction signaling, 
inhibiting cell growth and causing cell death [24]. 
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1.4.3 Chemotherapy 
Chemotherapy is administered in triple negative breast cancer patients; in 
ER-negative, PR-negative tumors overexpressing HER2, chemotherapy 
may be combined with anti-HER2 agents. Chemotherapy destroys breast 
cancer cells at the original tumor site and throughout the body. It represents 
a non-specific treatment that gives side effects. In fact, it can unintentionally 
strikes other types of rapidly dividing cells such as hair follicles, digestive 
tract, and bone marrow. Figure 2 shows a summary of therapeutic approach 
in breast cancer.  
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Figure 2. 
Schematic representation of the therapeutic approach in the various subtypes of breast 
cancer. 
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1.5 Cell cycle control in breast cancer 
 
Every cell that is part of a complex organism must decide his fate by 
proliferating or remaining in a state of quiescence; in an adult organism 
most of the cells are quiescent; on the contrary, specialized cells, such as 
hematopoietic system, and epithelium maintain active proliferation. 
Imbalance from a state of quiescence and active proliferation that occurs in 
cancer cells shows alteration in specific transduction pathway that  leads to 
an unchecked proliferation. 
Cell cycle is divided into four phases named G1, S, G2, M. In the S phase a 
cell generates a single copy of its genetic material; in M phase or mitosis it 
splits in two identical daughter cells. 
G1 and G2 represent gap periods during which cells prepare themselves for 
the successful completion of S and M phases. In absence of a mitogenic 
signal cell can enter into a quiescence state (G0). 
The central players of cell cycle are CDKs (cyclin dependent kinases) that 
form active heterodimeric complexes following the binding to cyclins. 
There are four CDKs: CDK1 regulates the transition from G2 to M phase 
while CDK2, CDK4 and CDK 6 regulate the transition from G1 to S phase. 
CDKs are finely regulated by activators (cyclins) and inhibitors (CKI). 
Different cyclins are required at different phases of the cell cycle. The three 
D type cyclins (cyclin D1, cyclin D2, cyclin D3) bind to CDK4 and to CDK6. 
Unlike the other cyclins, cyclin D is not expressed periodically, but is 
synthesized as long as growth factor stimulation persists. Cyclin E is 
another G1 phase cyclin; cyclinE – CDK2 complex regulates the 
progression from late  G1 into S phase. In S phase, cyclin A binds to CDK2; 
instead in G2 and early M, cyclin A complexes with CDK1 promoting the 
entry into M phase. Mitosis is further regulated by cyclin B in complex with 
CDK1. 
CKI are divided in two groups: the four member of the INK4 family (INK4A or 
p16, INK4B or p15, INK4C or p18 and INK4D or p19) that bind to the CDK4 
and CDK6 kinases by hindering their association with D - type cyclins, and 
the three member of WAF/KIP1 family (WAF1 or p21, KIP1 or p27, and 
KIP2 or p57) that inhibit  G0/G1 transition. An additional level of control is 
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conferred by specific kinases that regulate phosphorylation of specific 
threonine residues of activating (CAK) or inhibiting (WEE1, MYT1) CDK 
proteins. 
Progression from G1 to S phase is controlled by the Retinoblastoma  protein 
(pRb). Retinoblastoma prevents cell division by linking with E2F 
transcription factors and thereby inhibiting G1 to S transition. During G1 
phase growth signals stimulate cyclin D  to associate with CDK 4 or CDK 6. 
The complex cyclinD-CDK4/6 determines the Rb phosphorylation; this 
process stimulates the formation of other heterodimeric complex consisting 
of cyclinE-CDK2 by determining a state of complete Rb hyper-
phosphorylation. Rb then releases E2F allowing cell cycle progression 
through the activation of S-phase factors. 
In most breast cancer cases Rb does not shown genetic alteration; the 
minority of breast cancer (20%-30%) lost Rb expression; the incidence of 
Rb loss is dependent on the breast cancer subtype and is more common in 
triple negative breast cancer [25]. 
Also, Rb loss is associated to epithelial-mesenchymal transition and to 
metastasis formation [26]. 
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Figure 3. 
Cyclin D-CDK4/6-Rb protein pathway regulate cell cycle progression. CDK: Cyclin 
dependent kinase; Cip/Kip: Kinase inhibitor protein family; E2F: Elongation factor 2; INK4: 
Inhibitors of CDK4; P: Phosphate; Rb: Retinoblastoma protein [27].  
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1.6 New therapeutic approach in breast cancer 
About 75% of breast cancer is ER-positive. Estrogens can rise cell 
proliferation increasing the progression from G0 to G1 phase [28] 
[29].Currently, breast cancer therapy is based on the inhibition of estrogens 
synthesis (AIs), modulation of estrogen receptor (Tamoxifen) and its 
antagonists (Fulvestrant); this approach has resulted in a reduction of the 
proliferative stimulus at the level of breast tumor cells. Nevertheless, the 
development of resistance to endocrine therapy is a current real problem 
during endocrine therapy and novel studies on breast cancer drug 
resistance mechanisms are crucial for developing innovative therapeutic 
approaches. Cell cycle proteins are involved in the development of 
resistance to endocrine therapy; breast tumors ER-positive, Rb-negative 
mouse models are resistant to tamoxifene [30]. In addition, cyclin D1 
overexpression has been implicated in tamoxifen resistance, since the 
formation of heterodimers cyclin D1-CDK4/6 induces the withdrawal of p21 
and p27 with consequent activation of cyclin E-CDK2 complexes [31]. 
The combination of hormonal therapy with CDK4/6 inhibitors appears a 
promising strategy to overcome endocrine resistance [32]. 
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1.6.1 Therapeutic strategies at the level of CDK 
CDK are central players in the control of cell cycle progression. 
The complexity of CDK regulation emphasizes possible opportunity to their 
therapeutic inhibition. The most direct and successful strategies involve 
inhibitors that can block CDK activity [33]. 
Other possible strategies include: 1. Prevention of cyclin–CDK interaction 
with peptide-mimetics, CKI degradation or CKI function restoration by gene 
therapy; 2. Prevention of CKI degradation: KIP1 could involve either 
blocking phosphorylation, which triggers its degradation, or its interaction 
with SKP2, member of the SCF complex; 3. Decreasing of the levels of 
cyclin D1 by diminishing specific transcription of the gene by antisense 
techniques; 4. Increasing of protein degradation by their specific 
proteasomes. 5. Downregulation of positive regulators, such as the CAK or 
the CDC25 dual specificity phosphatases and/or  the activation of negative 
regulators, such as the dual specificity kinases WEE1 or MYT1 [34] [35]. 
 
 
1.6.2 Palbociclib 
The use of cell cycle inhibitors has not been successful in clinical practice 
since the first-generation compounds, known as pan-CDK inhibitors, 
exhibited considerable toxicity. The discovery of new compounds with 
favorable pharmaceutical and physical properties increased the interest in 
these types of compounds; they are highly selective and this characteristic 
has allowed a re-evaluation of their possible use in clinical practice. 
Palbociclib (also known as PD0332991) is one of the most promising CDK 
4/6 inhibitor developed from a group of pyridopyrimidine; it is a non-
competitive ATP inhibitor that inhibits CDK 4/6 at low nanomolar 
concentration in Rb proficient breast cancer cells (Figure 4) [36] . 
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Figure 4. 
Representation of the CDK 4/6 inhibitor Palbociclib. This compound consists of a group of 
piridopirimidine and is highly selective (order of nM) in the inhibition of cell proliferation [36]. 
 
Sensitivity to Palbociclib depends on molecular subtypes; Finn et al. have 
investigated the activity of Palbociclib in breast cancer cell lines 
representing several molecular subtypes and demonstrated that ER-positive 
breast cancer cell lines with luminal features are most sensitive to 
Palbociclib treatment compared to breast cancer cell lines with basal 
features, which are resistant [37]. 
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Figure 5. 
 Inhibitory concentration and breast cancer cell type. Bar graph  representing different  Cell 
lines are color coded by subtype: light blue, luminal; dark blue bars or stripes, HER2 
amplified; yellow, nonluminal/undergone an epithelial-to-mesenchymal transition; red, 
nonluminal; turquoise, immortalized [37].  
 
It has been demonstrated that Rb negative cells are resistant to Palbociclib 
[38]. The sensitivity to the drug is based on elevated level of Rb and cyclin 
D1 proteins and low levels of p16 protein [39]. Preliminary studies have 
evaluated the combined effect of Palbociclib with drugs currently used in 
breast cancer therapy. In ER-positive MCF-7 cells it shows a synergistic 
effect with tamoxifen and is able to re-sensitize the cells to tamoxifen. In  
HER2-positive breast cancer cell lines the synergistic effect of Palbociclib 
with Trastuzumab has been demonstrated [37]. 
The combined effect of Palbociclib with chemotherapy is associated with the 
type of drug used and with the presence or absence of Rb. Indeed, when 
associated with carboplatin, Palbociclib has shown a myeloprotective 
activity in mice lacking Rb expression, by inducing hematopoietic progenitor 
cells in a quiescent state without altering the activity of the drug. In mice 
expressing Rb, the combination of the two agents compromised the drug 
efficacy compared with carboplatin alone [40]. 
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1.6.3 Clinical development of Palbociclib 
Palbociclib was evaluated in a open-label dose finding phase I study in 
patients with Rb-proficient solid tumor. Thirty-three patients were enrolled 
and dose limiting toxicities (DLT) were observe at 225 mg/day,  200 mg/day 
was selected as the maximum tolerated dose (MTD) [41]. 
PALOMA-1 study (NCT00721409) is a multicenter, randomized phase I/II 
study, where ER-positive, HER2-negative breast cancer postmenopausal 
patients have been treated with palbociclib (at a dose of 125 mg orally daily 
on the 3on/1off) combined with letrozole 2.5 mg daily continuously versus 
letrozole alone [42]. 
Eligible patients have received either regimen as first line treatment for 
metastatic disease. The analysis of 165 patients enrolled has been 
impressive, and PFS increased over three fold in patients treated in the 
combination arm (26.1 vs. 7.5 months). Combination therapy was very well 
tolerated and the most frequent side effects were uncomplicated 
neutropenia (61.4% in patients treated with both agents compared with 
1.3% in patients treated with single-agent letrozole), leukopenia, anemia 
and fatigue. On the basis of these favorable results, the FDA designed 
palbociclib as a “breakthrough therapy” for metastatic breast cancer in 2015. 
A confirmatory phase III PALOMA-2 trial (NCT01740427) patients with 
previously untreated, advanced ER-positive, HER2-negative breast cancer 
are randomized to the combination of palbociclib and letrozole vs. letrozole 
alone. The analysis in progress revealed that PFS increased in patients 
treated in the combination arm (24.8 vs. 14.5 months) [43]. 
The double-blind phase III PALOMA-3 trial (NCT0192135) evaluated the 
efficacy of palbociclib and fulvestrant in pre- and post-menopausal women 
with ER-positive, HER2-negative advanced breast cancer who had 
progressed on prior endocrine therapy. Patients were randomized 2:1 to 
palbociclib and fulvestrant or to placebo and fulvestrant. Pre and peri-
menopausal women were also treated with the LhRh agonist, goserelin. At 
the first interim analysis, PFS was 9.2 months in the palbociclib and 
fulvestrant arm and 3.8 months in the placebo and fulvestrant arm. 
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On the basis of these results, palbociclib and fulvestrant represent a new 
treatment option for pre- and postmenopausal patients with ER-positive, 
HER2-negative advanced breast cancer who have progressed on prior 
endocrine therapy [44]. 
Currently, several trials evaluating efficacy of palbociclib and endocrine 
therapy are in progress in the adjuvant (NCT02040857) and neoadjuvant 
settings (NCT02400567, NCT01723774, NCT01709370) in patients with 
ER-positive, HER2-negative breast cancer. 
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2. AIM OF THE STUDY 
 
The aim of the study was to evaluate the effect of the cell cycle inhibitor 
Palbociclib (PD 0332991) on the proliferation of different subtype of breast 
cancer cell. To this aim we chose four breast cancer cell lines (MCF-7, 
MDA-MB-231, BT474Z, and MCF7/her2 transfected, which are MCF7 cells 
stably expressing HER2) and one primary breast cancer culture (K90) 
obtained from residual breast carcinoma tumor tissue from patients 
undergoing surgery at the ”Azienda Ospedaliera Universitaria Federico II”. 
We  identified breast cancer cells, representing different molecular breast 
cancer subtype, sensitive/resistant to drug treatment and evaluated whether 
the in vitro effect of Palbociclib was permanent or transient. Levels of cyclin 
D1, p27, and Rb phosphorylation (ser780) status have been investigated in 
Palbociclib treated  compared with untreated breast cancer cells. Variations 
in cell cycle phases have been observed by Facs analysis, following 
treatment with the drug. Finally, it has been evaluated in vitro the combined 
effect of Palbociclib  and Formestane on  breast cancer cell proliferation. 
In breast cancer, several specific molecular targeted-agents are used but 
the resistance to endocrine therapy still remains the main problem in the 
management of this disease.  
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3.  MATERIALS AND METHODS 
 
3.1 Breast cancer tissue collection 
 
For this study 58 fresh tissue specimens were collected from breast cancer 
patients who underwent surgery at the "Federico II" University of Naples, 
General Surgery Unit, whose clinical and pathological features are 
summarized in the following table: 
 
CLINICAL PARAMETERS NUMBER 
TOTAL NUMBER OF SAMPLES 58 
AVERAGE AGE (AGES) 
RANGE OF AGE(anni) 
57.3 
36-84 
HISTOLOGY   
DUCTAL ORIGIN  
LOBULAR ORIGIN 
OTHER 
48 
6 
4 
GRADING  
I 
II 
III 
1 
19 
38 
NODAL STATE  
POSITIVE 
NEGATIVE 
26 
32 
TUMOR STAGE  
T1 
T2 
T3 
T4 
28 
25 
3 
2 
 25 
 
C-erbB2 
  
ABSENT 
+ 
++ 
+++ 
38 
4 
6 
10 
 
Evaluation of protein expression (cyclinD1 and ERα ) was carried out on 34 
breast tissue specimens. 
This study was authorized by "Federico II" University Institutional Review 
Board.  
 
3.2 Cell lines 
 
Breast cancer cell lines MCF-7, MDA-MB-231 and BT474Z were obtained 
from ATCC (American Type Culture Collection). MCF-7 / her2 transfected 
cells were provided by Dr. R. Schiff’s group. MCF-7, MDA-MB-231 cells 
were maintained in standard medium consisting of DMEM (Sigma-Aldrich) 
supplemented with 2 mM glutamine (Sigma-Aldrich), 1% 
penicillin/streptomycin (Life Technologies, Carlsbad, CA, USA), 15 mM 
HEPES (Sigma-Aldrich) and 5% fetal bovine serum (FBS)  at 37°C in a 
humidified atmosphere of 5% CO2 ; BT474 cells were cultured in DMEM 
containing 10% FBS while MCF-7 / her2 transfected in DMEM containing 
10% FBS, insulin (5ug/ml) and G418 (gentamicin). 
Primary breast cancer cells (K90) were obtained directly from tumoral lesion 
[45] and maintained in standard medium consisting of DMEM/F12 1:1 
(Sigma-Aldrich) supplemented with 2 mM glutamine (Sigma-Aldrich), 1% 
penicillin/streptomycin (Life Technologies, Carlsbad, CA, USA), 15 mM 
Hepes (Sigma-Aldrich) and 5% foetal bovine serum (FBS) and  at 37°C in a 
humidified atmosphere of 5% CO2. 
 
 
3.3 Drugs 
 
Palbociclib (PD0332991) (Pfizer, NY, USA ) was dissolved in DMSO and 
used at different concentrations ranging from 31.25 nM to 1 mM. 
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Formestane (Sigma-Aldrich ) was dissolved in DMEM and used at different 
concentrations ranging from 25 nM to 600 nM. 
 
 
3.4 MTT assay 
 
Cell viability was determined using the colorimetric 3-4,5-dimethylthiazol-2-
yl-2,5-diphenyl tetrazolium bromide (MTT) assay (Sigma Aldrich). 
Exponentially growing cells (1 x 104 cells/well) were seeded in 24-well plates 
and cultured at 37˚C, under 5% CO2 for 24 h. Cells were treated with drugs 
for a maximum of six days. 
MTT (0,72 mg/ml) was resuspended in DMEM  and 500 µl of this 
resuspension was added to each well. After incubation at 37˚C for 4 h, 500 
µl isopropyl alcohol-HCl was added in each well and were placed in 
agitation in the dark for 20 minutes. The OD value was measured at a 
wavelength of 570 nm and 690 nm. Triplicates for each point were counted 
in 3 different experiments. 
 
3.5  Cell Count 
 
Cells were seeded in triplicate at 5 x 103 to 15 x 103 cells per well in 24-well 
plates. The day after, Palbociclib was added at concentration of 31.25 nM, 
62.5 nM, 125 nM, 250 nM, 500 nM, 1 µM for 6 days. Breast cancer cells 
were counted after 1,3 and 6 days. After trypsinization, cells were collected 
in a solution of DMEM / trypan blue 1:1 and counted by haemocytometer 
chamber. 
 
 
 3.6 Cell cycle analysis 
 
Breast cancer cells BT474, MCF-7, MCF7 /her2 trasfected and MDA-MB-
231  were treated with Palbociclib at a concentration of 1 uM for 12 hours. 
Cells  were trypsinized, collected in ice-coldPBS-10% FBS and centrifuged 
at 1500 rpm for 5 min;  then,  cells were washed twice with ice-cold PBS. 
For cell cycle analysis, cells were fixed in ice-cold ethanol (70%) and 
stained with 0.5 ml PI/RNase staining buffer (BD Pharmingen, USA) for 20 
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minutes at room temperature in the dark and analyzed by flow cytometry 
(Becton-Dickinson, Franklin Lakes, NJ, USA). 
 
3.7  Western Blot 
 
Western blotting was used to determine protein expression of estrogen 
receptor alpha and cyclin D1 on  tissue specimens and to evaluate cyclin 
D1, p27, Rb and Rb phosphorylated in serine 780 in breast cancer cell lines 
analysed (BT474, MCF-7, MCF-7 /her2 transfected and MDA-MB-231). 
Thirty-four breast cancer tissue specimens collected were processed as 
follows: 
1. Mechanical shredding with a scalpel 
2. Homogenization of the samples after the addition of lysis buffer (150 mM 
NaCl, 50 mM Tris pH 7.5, 0.5% NP-40, 1mM EDTA) containing a cocktail of 
protease and phosphatase inhibitors [Complete-EDTA FREE (Roche)], 20 
mM NaF, Na4O7P2 4 mM, β–glycerophosphate 5 mM and Na3VO42 mM]. 
3. Incubation on ice for 30 minutes 
4. Centrifugation at 4 ° C for 15 minutes at 13,200 rpm 
5. Collection of the supernatant containing the protein fraction of the lysate 
 
Breast cancer cells were seeded (5 x 10^5) in petri dish 100 mm at 37˚C 
under 5% CO2. After 24 hours, breast cancer cells were treated with 
Palbociclib  (31,25 nM to 1 uM for 6 days). Subsequently, cells were 
trypsinized and washed in PBS; after centrifugation (1500 rpm for 5 
minutes) cells were incubated in Ripa lysis buffer (Tris-HCl PH = 7.4  50 
mM,Sodium Deoxycholate 0.25 %, 150 mMNaCl, 1 % NP - 40, 1 mM EDTA, 
NaF 1 mM, 1 mM Na3VO4, sodium pyrophosphate 100 mM, protease 
inhibitor) for 30 minutes  on ice. 
Finally, cells and tissues lysates were centrifuged at 12,000 rpm for 20 
minat 4˚C. Protein concentrations were determined by Bradford assay. Fifty 
micrograms of protein from each total lysates were denatured in 4X sample 
buffer, loaded and separated on 10% sodium dodecyl sulfate-
polyacrylamide (SDS) electrophoresis gel. After electrophoresis, separated 
proteins were transferred onto PVDF membranes (Immobilion-P) followed 
by blocking with 5% non-fat milk  in Tris-buffered saline [10 mMTris-HCl (pH 
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7.5), 100 mMNaCl, 0.1% Tween-20) for 1 h at room temperature. The 
membranes were then incubated with specific primary antibodies: Rb 
(Mouse Mab 4H1 # 9309 Cell signalling Technologies, USA) and p-Rb 
ser.780 (Rabbit Mab C84F6 # 3590 ,Cell signalling Technologies, USA), 
cyclin D1 (# sc-717 , Santa Cruz Biotechnology), ERα (# sc-8005, Santa 
Cruz Biotechnology, USA) and p27 (# sc-1641, Santa Cruz Biotechnology, 
USA) overnight at 4°C. After washing, the membranes were incubated with 
appropriate secondary HRP-conjugated antibodies and visualized by ECL. 
Each membrane was reprobed with anti-tubulin (Monoclonal Anti α Tubulin 
Clone DM 1 A  # 9026 Sigma Aldrich, Milan)   antibody to ensure equal 
protein loading. 
 
3.8 RT-PCR analysis  
 
Total RNA was isolated from sample and control cells using TRIzol Reagent 
(Invitrogen, USA) according to the manufacturer’s instructions. Purity of 
RNA was checked by measuring the absorbance ratio at 260/280 nm in a 
Beckman Coulter spectrophotometer (Beckman Coulter, Fullertone, CA, 
USA) with appropriate purity values between 1.8 and 2.0. RNA was stored 
at -80°C. The integrity of RNA was assessed on standard 1% 
agarose/formaldehyde gel. The reverse transcription of 1.5 µg of total RNA 
was performed with SuperScript III reverse transcriptase Kit (Invitrogen, 
USA) according to the manufacturer’s instructions. Multiplex PCR was 
performed in 50 µL reactions  using the PTC-200 Peltier Thermal Cycler 
(Bio-Rad Laboratories, USA)  and gene specific sets of primers, including 
those for the internal standard β-actin. Agarose gel electrophoresis and 
staining with 0.3 mg/ml of ethidium bromide (Sigma, St. Louis, MO) were 
carried out to assess templates products. Primer sequences and PCR 
reactions steps are the following: 
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3.9 Statistical analysis 
Data are expressed as the mean derived from triplicate replications in each 
experiment. Significance was accepted at the p < 0.005. 
 30 
 
4.0 RESULTS 
 
4.1  Levels of cyclin D1 correlated with level of expression of estrogen 
receptor alpha in breast tumor tissues  
Cyclin D1 is essential for the regulation of breast cell division. Estrogen 
binding of ERα drives cyclin D1 transcription, activation of CDK4/6, 
phosphorylation of Rb and cell cycling [46]. However, cyclin D1 can activate 
ERα, transcription and cell division independently of estrogen and CDK. 
This independent activity is not inhibited by anti-estrogens strategies and is 
associated with endocrine resistance [47]. 
Given the relationship between the estrogen receptor, which acts as 
activator of proliferation, and cyclin D1 that promotes cell cycle progression, 
estrogen receptor and cyclin D1 protein expression have been evaluated in 
tumor tissues specimens derived from breast cancer  patients undergoing 
surgery at the Surgery Unit of “Azienda Universitaria di Napoli Federico II”.  
Thirty-four fresh-frozen tissue samples were analysed by Western blot to 
evaluate   estrogen receptor alpha  and cyclin D1 expression (figure 6). 
MCF-7 was used as breast cancer control cells and α-tubulin was used as 
loading control. 
Brest tumor tissue specimens 4, 6, 7, 8, 15, 16, 17, 18, 22, 23, 24, 25, 27, 
28, 33, 34 resulted ER - positive; on the contrary breast tissue specimens 1, 
2, 3, 5, 9, 10, 11,12, 13, 14, 19, 20, 21, 26, 29, 30, 31, 32 resulted ER-
negative. The evaluation of cyclin D1 expression revealed that breast tumor 
tissue specimens 1, 2, 4, 5, 6, 7, 8, 9, 11, 15, 16, 17, 18, 20, 22, 23, 24, 25, 
27, 28, 33, 34 are Cyclin D1-positive; conversely breast tumor tissue 
specimens 3, 10, 12, 13, 14, 19, 21, 26, 29, 30, 31, 32 are Cyclin D1-
negative. Densitometric analysis revealed that ER–positive tumor tissue 
specimens analysed express discriminable  levels of cyclin D1; on the 
contrary ER-negative breast tumor tissue specimens do not express cyclin 
D1, except for the sample 20.  Analysis performed revealed a correlation 
between ER-α and Cyclin D1 expression. This result indicates that 
activation of the estrogen receptor is closely associated with cyclin D1 
expression which represents its main downstream effector. 
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Figure 6. Quantitative analysis of estrogen receptor alpha and cyclin D1 protein 
expression on thirty four  breast tumor tissue specimens were evaluated. Protein 
expression was normalized on  α-tubulin expression; samples analyzed showed 
concomitant  expression of estrogen receptor  α and cyclin D1. 
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4.2 Palbociclib inhibits cell proliferation of human breast cancer cell 
lines 
To evaluate the role of Palbociclib on cell proliferation, the effects of the 
drug have been tested on a panel of 4 human breast cancer cells, consisting 
of MCF-7, MDA-MB-231, BT474, MCF7/her 2 transfected. 
The selected breast cancer cells display characteristics of molecular 
subtypes of breast cancer; MCF-7 is a breast cancer cell line derived from 
invasive breast  ductal carcinoma, from pleural effusion. They are ER-
positive PR-positive and HER2-negative. 
BT474 cell line was isolated from invasive ductal breast carcinoma; It is ER-
positive, PR-positive and HER 2-positive. 
MCF7/her2 transfected was provided by Dr. R. Schiff’s group (Department 
of Medicine, Baylor College of Medicine Houston, Texas).These breast 
cancer cells are MCF-7 stable transfected with a vector that allows HER2 
expression, and maintained in selective medium with geneticin.  
MDA-MB-231 are breast cancer cells isolated from pleural effusion having 
ER-negative, PR-negative,HER2-negative and representing a triple negative  
in vitro model. 
To confirm the receptor expression features of breast cancer cell lines,  
gene expression of different receptors used in the breast cancer 
classification  such as ERα, HER 2 and PR, have  been evaluated by RT-
PCR (Figure 7). MCF-7, BT474, MCF7/her2 transfected resulted ERα and 
PR positive; on the contrary MDA-MB-231 resulted PR and ERα  negative. 
The evaluation of HER 2 confirmed  MCF-7 and MDA-MB-231 as HER2-
negative; as expected BT474 and MCF7/her2 transfected were HER2-
positive.  
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Figure 7. mRNA expression (ERα, PR, HER 2) of 4 breast cancer cell subtypes selected. 
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To evaluate the effects of Palbociclib on cell proliferation, breast cancer 
cells were seeded for 24 hours in multiwells of 24 in triplicate. Once 
attached, cells were treated in vitro with scalar concentrations of drug (1 µM 
to 31,25 nM ). MTT assay and cell count were performed at 1 day, 3 days 
and 6 days of treatment.  
MTT assay revealed that Palbociclib displayed anti-proliferative activity after 
3 days in four different breast cancer cell lines at the different tested 
concentrations.  
Palbociclib does not alter MCF-7 cell proliferation after 24 hours; a dose 
dependent effect was observed after 3 days of treatment with a range of 
inhibition from 1% at 31,25 nM to 56% of inhibition at 1 µM compared to not 
treated control cells. Dose dependent effect persists after 6 days of 
treatment with a maximum of 80% inhibition of cell proliferation at 1 µM, 
compared to untreated cells. 
MDA-MB-231 cell proliferation is not altered when these cells are treated 
with palbociclib for 24 hours. The effect on proliferation becomes substantial 
after 3 days of treatment with a reduction of cell proliferation by 25 % at 250 
nM of drug concentration, and an inhibitory effect on cell growth up to 57 % 
at 1 uM. Interestingly, after 6 days of treatment, palbociclib displays the 
strongest inhibitory effect on cell growth (63 %),  at the maximum dose. 
In BT474 Palbocilib determines a reduction of cell proliferation (52 % of cell 
growth inhibition at 1 µM dose) after 3 days of treatment compared to 
untreated control cells. After 6 days of treatment a 66 % of inhibition was 
observed. 
Palbociclib determines a reduction of cell proliferation on MCF-7/ her2 
transfected with a cell growth inhibition of 60% after 6 days of treatment at 
the concentration of 1 µM . 
Cell count was performed after 1, 3 and 6 days after CDK4/6 inhibitor 
treatment. After 1 days of treatment at 1 µM of Palbociclib,  MCF-7 show a 
cell growth inhibition of 30%; 68% of growth inhibition was observed after 3 
days while 92% after 6 days of treatment. MDA-MB-231 resulted more 
resistant to Palbociclib compared to other breast cancer cells analyzed with 
27% of cell growth inhibition after 1 day, 43% after 3 days and 63% after 6 
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days of treatment. BT474 showed a slight inhibition of cell growth (3%) after 
1 day; 52% of inhibition was observed after 3 days of treatment and 81% 
was observed after 6 days of treatment. MCF-7/ her2 transfected showed 
16% of cell growth inhibition after 1 days of treatment, 67% of inhibition after 
3 days and 84% after 6 days of treatment with Palbociclib at 1µM (Figure 8). 
 
 
 
Figure 8. Study of cell proliferation  In breast cancer  cells (BT474; MCF-7; MCF-7 / her2 
trasfected; MDA-MB-231) following treatment with Palbociclib ; MTT assay (blu) and cell 
count (orange) were performed at different concentration (31.25 nM - 62.5 nM - 125 nM - 
250 nM - 500 nM - 1 uM) of the CDK4/6 inhibitor for 1, 3 and 6 days. MCF-7 resulted more 
sensitive to treatment compared to other breast cancer cells subtypes. 
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Based on MTT  data it was possible to calculate the IC 50 (Table 3).  
MCF-7 cell line (Luminal A) resulted  more sensitive to the treatment with an 
IC 50 equal to 201.5 nM. On the contrary, MDA-MB-231 cell line (Triple 
negative) was the most resistant to treatment with an IC 50 of 608 nM; 
MCF7/her2 transfected (Luminal B) show a IC 50 of 262 nM while BT474 
(Luminal B) show a IC50 of 384 nM.  
 
 
 
Table 3. Inhibitory concentration and cell type. Breast cancer cell lines  MCF-7 cells 
(Luminal A) are  sensitive to treatment with the CDK4/6 inhibitor Palbociclib; MDA-MB-
231 cells (Triple negative )  are more resistant compared to other breast cancer cell lines 
analysed. The expression of HER 2  receptor in MCF-7 / her2 transfected determines a 
greater resistance to in vitro treatment  than MCF-7  (262 nM vs 201 nM); BT474 cells 
(Luminal B) have a IC 50 value of 384 nM.   
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4.3 Palbociclib inhibits cell proliferation with a cytostatic effect 
In order to assess whether Palbociclib led to a cytostatic or cytotoxic effect 
on different breast cancer subtypes, the resumption of cells proliferation 
after in vitro  treatment with Palbociclib was evaluated. 
Residual breast cancer cells (20% of MCF-7,  37 % of MDA-MB-231, 34 % 
of BT474 and 24% of MCF-7/ her2 trasfected), after 6 days of treatment with 
Palbociclib at concentration of 1 µM, were detached and seeded again. 
Cell proliferation was evaluate by cell count after 1,3 and 6 days from 
seeding; breast cancer cells not previously treated were used as controls. 
All breast cancer cells analyzed, resumed to proliferate in a manner 
comparable with control cells, never treated with Palbociclib. The same 
sensitivity to the drug was observed when treating re-proliferating breast 
cancer cells again with Palbociclib at 31,25 nM, 62,5 nM, 125 nM, 250 
nM,500 nM and 1µM for 6 days; Figure 9 shows the cytostatic effect of 
Palbociclib. 
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Figure 9. Palbociclb determines a cytostatic effect in breast cancer cell line analyzed. After 
6 days of  treatment with the inhibitor at 1 uM cells were tripsinized and seeded again 
(arrow in the figure). Cell proliferation resumed and was comparable with control cells not 
previously  treated with the inhibitor. On the right Palbociclib inhibits cell proliferation  of 
treating breast cancer cells  again. BT474Z are orange, MCF-7 are blue, MCF-7/her2 
trasfected in green and MDA-MB-231 are in red .  
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4.4 Effect of Palbociclib in cell cycle protein modulation (cyclin D1, p27, 
Rb, pRb)   depends of  breast cancer cells subtypes  
 
To evaluate the effect of Palbociclib on cell cycle, I compared breast cancer 
cell lines untreated and breast cancer cell lines treated with Palbociclib at 1 
µM for 12 hours performing flow cytometry using propidium iodide. 
In all  breast cancer cells analyzed G0/G1 phase increased following 
treatment with the drug; In BT474Z  control cells, percentage of G0/G1 
phase was 59,42%; in BT474Z treated for 12 hours with Palbociclib the 
percentage of cells in G0/G1 increased to 71,2%. The percentage difference 
between treated and untreated cells was 11,78%. In MCF-7, G0/G1 phase 
was 77,65% in control cells; following treatment for 12 hours with Palbociclib 
(µM)  G0/G1 percentage was 97,97%. In addition, MCF7/her2 control cells 
showed 33,97% in G0/G1 phase; the increase of percentage of G0/G1 
phase in MCF7/her2 treated cells  was 7,08%  compare to control cells not 
treated. In triple negative MDA-MB-231 G0/G1 percentage in treated cells 
was 82,94 % compared to cells not treated  with the drug (62,07%).In this 
case,  percentage of difference between treated and untreated cells    was 
20.87%.  Furthermore, a decrease of S phase was observed following 
treatment with Palbociclib at 1 µM in BT474 (8,47% vs 17,9%), MCF-7 
(1.74% vs 15,81%) and MDA-MB-231 (4,09% vs 13,21%). In  MCF-7/her2 
transfected  percentage of S phase in control cells untreated was 15,53% 
while in treated cells with the inhibitor (1µM) was 11,93%. 
We did not observe obvious differences  of percentage in   G2/M phase in 
BT474Z (11,46% vs 12,45%)  and MCF-7/her2 transfected (17,59% vs 
16,54%) treated and not treated cells with Palbociclib (1µM) for 12 hours ; 
on the contrary MCF-7 (0,25% vs 6,25%) and MDA-MB231 (10,45% vs 
23,04%) showed a decrease of percentage in G2/M phase in treated cells 
compared to untreated breast cancer control cells. 
These results demonstrate that Palbociclib determines a cell cycle arrest in 
G0/G1 phase in all the four breast cancer cells analyzed (BT474Z, MCF-7, 
MCF7/her2 transfected and MDA-MB-231) (Figure 10).  
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Figure 10. Cell cycle analysis (left panels) and levels of expression of cyclin D1, p27, Rb 
and pRb in breast cancer cells (right panels). G0/G1 arrest was observed in breast cancer 
cells BT474Z (A), MCF-7 (B) MCF-7-HER2 (C) and  MDA-MB-231 (D) treated compared to 
control cells .  
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Rb is a tumor suppressor that plays a critical role in overcoming the 
restriction point from  G0 to G1 phase. During the G1 phase of the cell 
cycle, the cyclin D1- CDK4/6 complex stimulates the phosphorylation of 
tumor suppressor Rb promoting cell cycle progression. The effect at 
different concentration (62,5 nM, 250 nM, 1 uM) of Palbociclib after 6 days 
of treatment on total Rb and pRb (phosphorylation of serine780), Cyclin D1 
and p27 expression was determined in breast cancer cell lines BT474Z, 
MCF-7, MCF-7/her2 transfected and MDA-MB-231 breast cancer cell lines 
(Figure 10, right). No modulation in the expression of total Rb was found in 
the 4 breast cancer cells treated with the inhibitor of the complex CDK 4/6-
cyclin D1; conversely, in the phosphorylation of Rb at the level of serine 780 
differences were evident in BT474 and MCF-7 treated with Palbociclib at 
concentration of  1 uM  for 6 days compared to their untreated controls. 
A decrease of Rb phosphorylation was observed  with exposure to 
Palbociclib at 1 uM in BT474 and MCF-7; no change in MDA-MB-231  and 
in MCF-7/her2 transfected was  observed in the Rb phosphorylation status. 
Cyclin D1 protein expression is modulated differently depending on the 
breast cancer cells subtype; in MCF-7 and in MCF-7/ her2 transfected  
cyclin D1 expression increased in treated cells compared to untreated cells. 
In BT74Z cells (Luminal B ) Cyclin D1 expression decreased in treated cells 
(250 nM and 1 µM) compared to untreated control cells. MDA-MB-231 
(Triple negative) showed a specific expression of cyclin D1 characterized by 
the formation of a doublet. 
In MDA-MB-231 and  MCF-7/her2 transfected treated with Palbociclib, p27 
protein expression was reduced compared to untreated control cells; on the 
contrary no significant changes were observed in treated and untreated 
breast cancer cells MCF-7 and BT474Z. 
These results showed that in breast cancer cell lines more sensitive to the 
drug such as MCF-7 (Luminal A) and BT474Z (Luminal B) expression of  
endogen inhibitor p27 persists in treated cells; on the contrary, in cells   
resistant  to Palbociclib  p27 expression was reduced in treated compared to 
untreated cells.   
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4.5 The inhibition of cell proliferation increases if  Palbociclib is 
associated with Formestane  
In breast cancer, the inhibition of estrogen synthesis is an effective 
treatment for breast patients in menopause; however, patients may develop 
drug resistance.  
The effect of combination of AI Formestane and the CDK4/6 inhibitor was 
estimated on in vitro cell proliferation. 
MCF-7, BT474, MCF-7 / her2 transfected,  are ER-positive but Aromatase-
negative; MDA-MB-231 is ER-negative and  expresses low level of 
aromatase, enzyme capable of converting androgens to estrogens. 
In order to find the right candidate for the  the Palbociclib-Formestane  
combination study, it was evaluated the estrogen receptor alpha and 
aromatase (CYP19A1) expression of 11 breast primary breast cancer cells 
obtained directly from  fresh tumor tissue specimens [45]. 
K 90 primary breast cells were selected as ideal candidate for the analysis 
since they resulted to be positive for the expression of estrogen receptor 
and aromatase; MCF-7 was used as negative control (Figure 11A). 
K 90 and MCF-7 were seeded (15 x 10^3 in triplicate in 24 multiwells) and, 
after 24 hours, the cells were treated with increasing concentrations (25 nM, 
50 nM, 100 nM, 150 nM, 300 nM, 600 nM) of Formestane (AI) alone, 
Palbociclib alone (1 uM) and with a combination of  Formestane (at 
increasing concentrations)  and  Palbociclib  (1 µM)  for 6 days. 
MTT assay was performed to measure cell viability.  
In MCF-7, Formestane alone is not able to inhibit cell proliferation whereas 
Palbociclib alone, as previously shown, greatly inhibits MCF-7 cell 
proliferation (80% inhibition). Moreover, combined effect of Palbociclib and 
Formestane does not show a greater effect than Palbociclib alone. 
Interestingly, in K 90, Formestane alone displays a dose dependent effect 
with 61% of inhibition of cell proliferation at 600 nM compared to not treated 
control cells; palbociclib alone reduces the cell proliferation of 41% 
compared to untreated control cells.  
The combined effect  of the two compounds greatly inhibits (81,7%) breast 
cancer cell proliferation (Figure 11B). 
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Figure 11. In (A) selection of primary breast cancer cell K 90; MCF-7, MDA-MB-231, 
BT474 and MCF-7/ her2 trasfected don’t express aromatase. K 90 expresses estrogen 
receptor and aromatase (circle blu in figure); IN (B) on the left Formestane has not 
effect alone in MCF-7 (blu bars) and the effect on cell proliferation is due to Palbociclib ; 
on the right K 90 were treated with different concentration of Formestane alone (25 nM 
to 600 nM), Palbociclib alone (1 uM of concentration) and  Formestane at different 
concentration plus Palbociclib  at 1 uM. The combined effect determines a greater 
inhibition of cell proliferation compared single drug. 
 
 
On the basis of these results a dual targeted strategy, that determines the 
arrest of the proliferative stimulus induced by the inhibition of estrogen 
synthesis and the inhibition of the cell-cycle progression in G0/G1 phase 
could give important indications for use in clinical practice. 
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5. Discussion 
 
In this project, I describe Palbociclib, PD 0332991, as a potent and highly 
selective inhibitor of CDK 4 and CDK 6 and show that the suppression of the 
cell cycle regulators in human breast cancer cells  results in significant 
antiproliferative activity. PD 0332991 was tested on 3 breast cancer cells 
subtypes ( MCF-7, BT474Z, MDA-MB-231 ) representing 3 main subtypes of 
breast cancer ( Luminal A, Luminal B and triple negative ) and on MCF-7 
her 2/transfected to evaluate a possible role of HER 2 in response to 
Palbociclib. 
In the first part of the study I observed a concomitant expression of level of 
cyclin D1 and ERα in breast cancer tissue specimens; the correlation of this 
expression prompt me to evaluate the in vitro effect of Palbociclib (cyclin D1 
– CDK 4 inhibitor ) in ER-positive and ER-negative breast cancer cells lines 
to understand the effect on cell proliferation. Palbociclib induced an 
inhibition of cell proliferation on the 4 breast cancer cell lines analysed; 
MCF-7 cells were the most sensitive to treatment with IC 50 of 201 nM.  
The effect exerted by the drug is cytostatic; indeed, the different subtypes of 
breast cancer cells treated for 6 days with the inhibitor grew if they were 
cultured again. In addition, cell cycle regulatory proteins are modulated by 
the drug depending by cell subtype and the inhibition of cell proliferation can 
be increased if the drug is associated with AI. 
As observed in the present study and by Finn and colleagues [37] the drug 
displays a better inhibitory effect on luminal breast cancer cells growth; on 
the contrary basal type breast cancer cells are more resistant to the drug. 
These data are  supported by the inhibition of the Rb phosphorylation 
observed in MCF-7 and BT474 but not in MDA-MB-231. Further studies are 
needed to understand the lack of inhibition of Rb phosphorylation in certain 
cell types of breast cancer; a possible mutation in the binding site of CDK4/6 
or overexpression of complex CDK1/2-cyclin E, inactivating checkpoint at 
the level of the G1 phase may be a possible hypotheses. Also, amplification 
or overexpression of cyclin D1 is more frequently associated to Luminal A 
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subtype and the effect of estrogens is tightly connected to cyclin D1 
expression [48] . The in vitro effect of the Palbociclib on cancer growth  is 
cytostatic. However   some studies reveal a possible cytotoxic effect. Uras  
and colleagues [49] have demonstrated a cytotoxic effect of the drug on 
leukemia cells; indeed CDK4/6 kinase inhibition induced cell cycle arrest 
and apoptosis in FLT3-ITD leukemic cells; Hu W and colleagues [50] have 
shown no change in apoptosis in Human bone marrow mononuclear cells 
following treatment with Palbociclib. These works suggest that the drug 
activity can  depend on the cellular  type. 
In breast cancer, Palbociclib has showed synergistic effects with drugs such 
as tamoxifen and trastuzumab and a more complex effect with DNA-
damage agents [37]; in the present study Palbociclib along with AI is able to 
greatly inhibit cell proliferation of primary K 90 breast cancer. Further studies 
are needed to evaluate the effects of Palbociclib in combination with other 
drugs used in breast cancer and to evaluate its possible clinical use  in the 
different stages of this disease. 
 
6. Conclusions 
 
The purpose of this study was to identify subtypes of breast cancer more 
sensitive to the treatment with palbociclib. The results clearly show an 
inhibitory effect on the proliferation of Luminal A (ER- positive) and Luminal 
B (ER-positive, HER2- positive) breast cancer cells. 
However, in vitro and in vivo combination studies with specific targeted 
drugs (Trastuzumab, AIs , Fulvestrant) are needed to obtain information to 
help to guide patient selection in the clinic. 
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